Bendamustine hydrochloride - A renaissance of alkylating strategies in anticancer medicine

Drugs of Today

Volumn 45, Issue 6, 2009, Pages 431-444

  Eichbaum, Michael H R ^a   Bischofs, E ^a   Nehls, K ^a   Schneeweiss, A ^a   Sohn, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; CARBOPLATIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISONE; RIBOMUSTINE; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ALLERGIC REACTION; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; HYPOTENSION; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMATITIS; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; VOMITING;

ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS;

EID: 70350048900     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.6.1376696     Document Type: Review

References (34)

1. Chabber, B.A., Roberts, T.G. Chemotherapy and the war on cancer. Nat Rev Cancer 2005, 5(1): 65-72.
2. Zhong, W.X., Ditsworth D., Bauer, D.E., Wang, Z.Q., Thompson, C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004, 18(11): 1272-1282 (Pubitemid 38720595)
3. Wooley, D.W. Some biological effects produced by benzimidazole and their reversal by purines. J Biol Chem 1944, 152: 225-232
4. Strumberg D., Harstrick A., Doll K., Hoffmann B., Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996; 7(4): 415-421 (Pubitemid 26249195)
5. Apostolopoulos, C., Casteltano, L., Stebbing, I., Giamas, G. Bendamustine as a model for the activity of alkylating agents. Future Oncol 2008, 4(3): 323-332 (Pubitemid 351984083)
6. Ozegowski, W., Krebs, D. IMET 3393, (-[1-methyl-5-bis-(chloroethyl)- amino-benzimidazolyl-(2)]-butryric) acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds. Zbl Parm 1971, 110: 1013-1019
7. Gandhi, V. Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies. Semin Oncol 2002, 29 (4, Suppl. 13): 4-11.
8. Gaul, L., Manl-Weber, S., Baumann, P., Emmerich, B., Schmidtmaier, R. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: The role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 2008, 134(2): 245-253 (Pubitemid 350234070)
9. Leoni, L.M., Bailey, B., Reifert, J. et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008, 14(1): 309-317
10. Bergmann, M.A., Goebeler, M.E., Herold, M. Et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL study group. Haematologica 2005, 90(10):1357-1364
11. 14C] bendamustine in rat urine and bile: Preliminary structural identification of metabolites. Drug Metab Dispos 2007, 35(10): 1744-1753 (Pubitemid 47481565)
12. Schmidt-Hieber, M., Busse, A., Reufi, B., Knauf, W., Thiel, E., Blau, I.W. Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro. J Cancer Res Clin Oncol 2009, 135(2): 227-234
13. Keating, M.J., Bach, C., Yasothan, U., Kirkpatrick, P. Bendamustine. Nat Rev Drug Discovery 2008, 7(6): 473-474
14. Knauf, W. Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2009, 9(2): 165-74.
15. Kalaycio, M. Bendamustine: A new look at an old drug. Cancer 2009, 115(3): 473-479
16. Food and Drug Administration. FDA labelling information (online), www.fda.gov, 2008.
17. Pönisch, W., Mitrou, P.S., Merkte, K. et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - A randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006, 132(4): 205-212 (Pubitemid 43144255)
18. Pönisch, W., Rozanski, M., Goldschmidt, H. et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: Results of a phase I clinical trial. Br J Haematol 2008, 143(2): 191-200.
19. Friedberg, J.W., Cohen, P., Chen, L. et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 2008, 26(2): 204-210
20. Robinson, K.S., Williams, M.E., van der Jagt, R.H. et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26(27): 4473-4479
21. Rummel, M.J., Al-Batran, S.E., Kim, S.Z. et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin lymphoma. J Clin Oncol 2005, 23(15): 3383-3389
22. Herold, M., Schulze, A., Niederwieser, D. et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: Results of a randomised phase III trial. J Cancer Res Clin Oncol 2006, 132(2): 105-112
23. Rummel, M.J., von Gruenhagen, U., Niederle, N. et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: Results of a randomized phase III study of the Study group Indolent Lymphomas (StiL). Proc ASH 2008, Abst 2596.
24. Heider, A., Niederle, N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001, 12(9): 725-729 (Pubitemid 33001185)
25. Kahl. B. et al. Bendamustine is safe and effective in patients with rituximab-refractory, Indolent B-cell non-Hodgkin lymphoma. Proc ASH 2007, Abst 1351.
26. Weide, R., Hess, G., Köppler, H. et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007, 48(7): 1299-1306
27. Koenigsmann, M., Knauf, W., Herold, M. et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma - A multicenter phase I/II trial of the East German Society of Haematology and Oncology. Leuk Lymphoma 2004, 45(9): 1821-1827 (Pubitemid 39004071)
28. Bottke, D., Bathe, K., Wiegel, T., Hinkelbein, W. Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol 2007, 183(3): 128-132 (Pubitemid 46364895)
29. Loibl, S., Murmann, C., Schwedler, K. et al. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel In patients with pre-treated metastatic breast cancer: RiTa trial. Cancer Chemother Pharmacol 2009, 65(5): 953-958
30. Eichbaum, M.H., Schuetz, F., Khbeis, T., Lauschner, I., Foerster, F., Sohn, C., Schneeweiss, A. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer. Final results of a phase Il study. Anticancer Drugs 2007, 18(8): 963-968
31. von Minckwitz, G., Chernozemsky, I., Sirakova, L. et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): A phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005, 16(8): 871-877 (Pubitemid 41215753)
32. Köster, W., Heider, A., Niederle, N. et al. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol 2007, 2(4): 312-6. (Pubitemid 47181714)
33. Hartmann, J.T., Mayer, F., Schleicher, J. et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: A noncomparative multicenter phase 2 study of the German Sarcoma Group (AIO-001). Cancer 2007, 110(4): 861-866 (Pubitemid 47257665)
34. Schmidt-Hieber, M., Schmittel, A., Thiel, E., Keilholz, U. A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal cancer. Melanoma Res 2004, 14(6): 439-442 (Pubitemid 40221132)